{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:24:28Z","timestamp":1783949068345,"version":"3.55.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MCNT1-2023-12377456"],"award-info":[{"award-number":["PNRR-MCNT1-2023-12377456"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["Tele21-A5"],"award-info":[{"award-number":["Tele21-A5"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-05966-5","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T03:55:08Z","timestamp":1766116508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["IL-1 signaling and inflammasomes in acute myeloid leukemia: mechanisms and therapeutic opportunities"],"prefix":"10.1007","volume":"82","author":[{"given":"Alessandra","family":"Mortellaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mastaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"5966_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"5966_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"5966_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"5966_CR4","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S et al (2018) Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378:2386\u20132398. https:\/\/doi.org\/10.1056\/NEJMoa1716984","journal-title":"N Engl J Med"},{"key":"5966_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"5966_CR6","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526\u20132537. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"},{"key":"5966_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/bloodadvances.2020003709","volume":"5","author":"S Stratmann","year":"2021","unstructured":"Stratmann S, Yones SA, Mayrhofer M et al (2021) Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. Blood Adv 5:900\u2013912. https:\/\/doi.org\/10.1182\/bloodadvances.2020003709","journal-title":"Blood Adv"},{"key":"5966_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381:1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"5966_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5966\/sctm.2013-0166","volume":"3","author":"E Griessinger","year":"2014","unstructured":"Griessinger E, Anjos-Afonso F, Pizzitola I et al (2014) A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl Med 3:520\u2013529. https:\/\/doi.org\/10.5966\/sctm.2013-0166","journal-title":"Stem Cells Transl Med"},{"key":"5966_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000896","volume":"7","author":"C Tomasoni","year":"2023","unstructured":"Tomasoni C, Pievani A, Rambaldi B et al (2023) A question of frame: the role of the bone marrow stromal niche in myeloid malignancies. Hemasphere 7:e896. https:\/\/doi.org\/10.1097\/HS9.0000000000000896","journal-title":"Hemasphere"},{"key":"5966_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta DB, Varela VA, Datoguia TS et al (2021) The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front Cell Dev Biol 9:764698. https:\/\/doi.org\/10.3389\/fcell.2021.764698","journal-title":"Front Cell Dev Biol"},{"key":"5966_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.37349\/etat.2024.00262","volume":"5","author":"S Khattab","year":"2024","unstructured":"Khattab S, El Sorady M, El-Ghandour A et al (2024) Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche. Exploration of Targeted Anti-tumor Therapy 5:1027\u20131055. https:\/\/doi.org\/10.37349\/etat.2024.00262","journal-title":"Exploration of Targeted Anti-tumor Therapy"},{"key":"5966_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/2643-3230.BCD-23-0125","volume":"4","author":"LE Lisi-Vega","year":"2023","unstructured":"Lisi-Vega LE, M\u00e9ndez-Ferrer S (2023) The inflamed niche: a double-edged sword in AML? Blood Cancer Discov 4:349\u2013351. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0125","journal-title":"Blood Cancer Discov"},{"key":"5966_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.34684","volume":"154","author":"C Allert","year":"2024","unstructured":"Allert C, M\u00fcller-Tidow C, Blank MF (2024) The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia. Int J Cancer 154:197\u2013209. https:\/\/doi.org\/10.1002\/ijc.34684","journal-title":"Int J Cancer"},{"key":"5966_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102526","volume":"82","author":"B Wang","year":"2025","unstructured":"Wang B, Reville PK, Abbas HA (2025) Therapeutic hurdles in acute myeloid leukemia: leukemic stem cells, inflammation and immune dysfunction. Curr Opin Pharmacol 82:102526. https:\/\/doi.org\/10.1016\/j.coph.2025.102526","journal-title":"Curr Opin Pharmacol"},{"key":"5966_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41375-024-02136-7","volume":"38","author":"D-W Chen","year":"2024","unstructured":"Chen D-W, Fan J-M, Schrey JM et al (2024) Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche. Leukemia 38:741\u2013750. https:\/\/doi.org\/10.1038\/s41375-024-02136-7","journal-title":"Leukemia"},{"key":"5966_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1000996","author":"M Luciano","year":"2022","unstructured":"Luciano M, Krenn PW, Horejs-Hoeck J (2022) The cytokine network in acute myeloid leukemia. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1000996","journal-title":"Front Immunol"},{"key":"5966_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1080\/10428194.2023.2218508","volume":"64","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tang X, Zhu Y et al (2023) Role of interleukins in acute myeloid leukemia. Leuk Lymphoma 64:1400\u20131413. https:\/\/doi.org\/10.1080\/10428194.2023.2218508","journal-title":"Leuk Lymphoma"},{"key":"5966_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcyt.2020.01.001","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, Sun X, Yuan S et al (2020) Interleukin-1\u03b2 inhibits normal hematopoietic expansion and promotes acute myeloid leukemia progression via the bone marrow niche. Cytotherapy 22:127\u2013134. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.001","journal-title":"Cytotherapy"},{"key":"5966_CR20","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.3324\/haematol.2020.254987","volume":"106","author":"B De Boer","year":"2021","unstructured":"De Boer B, Sheveleva S, Apelt K et al (2021) The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis. Haematologica 106:3067\u20133078. https:\/\/doi.org\/10.3324\/haematol.2020.254987","journal-title":"Haematologica"},{"key":"5966_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood.V78.3.849.849","volume":"78","author":"HD Preisler","year":"1991","unstructured":"Preisler HD, Raza A, Kukla C et al (1991) Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia. Blood 78:849\u2013850","journal-title":"Blood"},{"key":"5966_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1006\/cyto.2000.0666","volume":"12","author":"M Tao","year":"2000","unstructured":"Tao M, Li B, Nayini J et al (2000) SCF, IL-1\u03b2, IL-1ra AND GM-CSF IN THE BONE MARROW AND SERUM OF NORMAL INDIVIDUALS AND OF AML AND CML PATIENTS. Cytokine 12:699\u2013707. https:\/\/doi.org\/10.1006\/cyto.2000.0666","journal-title":"Cytokine"},{"key":"5966_CR23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","volume":"50","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dinarello CA, Molgora M, Garlanda C (2019) Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50:778\u2013795. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.012","journal-title":"Immunity"},{"key":"5966_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imr.12606","volume":"281","author":"D Boraschi","year":"2018","unstructured":"Boraschi D, Italiani P, Weil S, Martin MU (2018) The family of the interleukin-1 receptors. Immunol Rev 281:197\u2013232. https:\/\/doi.org\/10.1111\/imr.12606","journal-title":"Immunol Rev"},{"key":"5966_CR25","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e21","volume":"24","author":"DH Kim","year":"2024","unstructured":"Kim DH, Lee W-W (2024) IL-1 receptor dynamics in immune cells: orchestrating immune precision and balance. Immune Netw 24:e21. https:\/\/doi.org\/10.4110\/in.2024.24.e21","journal-title":"Immune Netw"},{"key":"5966_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133354","volume":"14","author":"M Pereira","year":"2023","unstructured":"Pereira M, Gazzinelli RT (2023) Regulation of innate immune signaling by IRAK proteins. Front Immunol 14:1133354. https:\/\/doi.org\/10.3389\/fimmu.2023.1133354","journal-title":"Front Immunol"},{"key":"5966_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804641","volume":"13","author":"D Supino","year":"2022","unstructured":"Supino D, Minute L, Mariancini A et al (2022) Negative regulation of the IL-1 system by IL-1R2 and IL-1R8: relevance in pathophysiology and disease. Front Immunol 13:804641. https:\/\/doi.org\/10.3389\/fimmu.2022.804641","journal-title":"Front Immunol"},{"key":"5966_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/imr.12609","volume":"281","author":"M Molgora","year":"2018","unstructured":"Molgora M, Supino D, Mantovani A, Garlanda C (2018) Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8. Immunol Rev 281:233\u2013247. https:\/\/doi.org\/10.1111\/imr.12609","journal-title":"Immunol Rev"},{"key":"5966_CR29","doi-asserted-by":"publisher","unstructured":"Dunne A, O\u2019Neill LAJ (2003) The interleukin-1 receptor\/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003:re3. https:\/\/doi.org\/10.1126\/stke.2003.171.re3","DOI":"10.1126\/stke.2003.171.re3"},{"key":"5966_CR30","doi-asserted-by":"publisher","first-page":"cm1","DOI":"10.1126\/scisignal.3105cm1","volume":"3","author":"A Weber","year":"2010","unstructured":"Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3:cm1\u2013cm1. https:\/\/doi.org\/10.1126\/scisignal.3105cm1","journal-title":"Sci Signal"},{"key":"5966_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1084\/jem.166.5.1597","volume":"166","author":"K Sakai","year":"1987","unstructured":"Sakai K, Hattori T, Matsuoka M et al (1987) Autocrine stimulation of interleukin 1 beta in acute myelogenous leukemia cells. J Exp Med 166:1597\u20131602. https:\/\/doi.org\/10.1084\/jem.166.5.1597","journal-title":"J Exp Med"},{"key":"5966_CR32","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1073\/pnas.86.7.2369","volume":"86","author":"F Cozzolino","year":"1989","unstructured":"Cozzolino F, Rubartelli A, Aldinucci D et al (1989) Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci U S A 86:2369\u20132373. https:\/\/doi.org\/10.1073\/pnas.86.7.2369","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5966_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.1989.tb00241.x","volume":"42","author":"A Erroi","year":"1989","unstructured":"Erroi A, Specchia G, Liso V et al (1989) Interleukin-1 and tumor necrosis factor production in acute non-lymphoid leukemia. Eur J Haematol 42:16\u201323. https:\/\/doi.org\/10.1111\/j.1600-0609.1989.tb00241.x","journal-title":"Eur J Haematol"},{"key":"5966_CR34","first-page":"898","volume":"6","author":"M Yin","year":"1992","unstructured":"Yin M, Gopal V, Banavali S et al (1992) Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells. Leukemia 6:898\u2013901","journal-title":"Leukemia"},{"key":"5966_CR35","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/blood.V78.12.3248.3248","volume":"78","author":"A Rambaldi","year":"1991","unstructured":"Rambaldi A, Torcia M, Bettoni S et al (1991) Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 78:3248\u20133253","journal-title":"Blood"},{"key":"5966_CR36","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1182\/blood.V79.8.1938.1938","volume":"79","author":"Z Estrov","year":"1992","unstructured":"Estrov Z, Kurzrock R, Estey E et al (1992) Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79:1938\u20131945","journal-title":"Blood"},{"key":"5966_CR37","first-page":"133","volume":"18","author":"I Murohashi","year":"1990","unstructured":"Murohashi I, Tohda S, Suzuki T et al (1990) Mechanism of action of Interleukin 1 on the progenitors of blast cells in acute myeloblastic leukemia. Exp Hematol 18:133\u2013137","journal-title":"Exp Hematol"},{"key":"5966_CR38","first-page":"44","volume":"4","author":"D Bradbury","year":"1990","unstructured":"Bradbury D, Bowen G, Kozlowski R et al (1990) Endogenous interleukin-1 can regulate the autonomous growth of the blast cells of acute myeloblastic leukemia by inducing autocrine secretion of GM-CSF. Leukemia 4:44\u201347","journal-title":"Leukemia"},{"key":"5966_CR39","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1182\/blood.V76.8.1481.1481","volume":"76","author":"JC Rodriguez-Cimadevilla","year":"1990","unstructured":"Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L et al (1990) Coordinate secretion of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as an endogenous inducer. Blood 76:1481\u20131489","journal-title":"Blood"},{"key":"5966_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.168.2.463","volume":"168","author":"T Hoang","year":"1988","unstructured":"Hoang T, Haman A, Goncalves O et al (1988) Interleukin 1 enhances growth factor-dependent proliferation of the clonogenic cells in acute myeloblastic leukemia and of normal human primitive hemopoietic precursors. J Exp Med 168:463\u2013474. https:\/\/doi.org\/10.1084\/jem.168.2.463","journal-title":"J Exp Med"},{"key":"5966_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1365-2141.1990.tb07905.x","volume":"76","author":"D Bradbury","year":"1990","unstructured":"Bradbury D, Rogers S, Kozlowski R et al (1990) Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia. Br J Haematol 76:488\u2013493. https:\/\/doi.org\/10.1111\/j.1365-2141.1990.tb07905.x","journal-title":"Br J Haematol"},{"key":"5966_CR42","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ijc.2910460525","volume":"46","author":"F Cozzolino","year":"1990","unstructured":"Cozzolino F, Torcia M, Bettoni S et al (1990) Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia. Int J Cancer 46:902\u2013907. https:\/\/doi.org\/10.1002\/ijc.2910460525","journal-title":"Int J Cancer"},{"key":"5966_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35700-9","volume":"14","author":"A Villatoro","year":"2023","unstructured":"Villatoro A, Cuminetti V, Bernal A et al (2023) Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. Nat Commun 14:12. https:\/\/doi.org\/10.1038\/s41467-022-35700-9","journal-title":"Nat Commun"},{"key":"5966_CR44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200560","volume":"218","author":"KC Higa","year":"2021","unstructured":"Higa KC, Goodspeed A, Chavez JS et al (2021) Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors. J Exp Med 218:e20200560. https:\/\/doi.org\/10.1084\/jem.20200560","journal-title":"J Exp Med"},{"key":"5966_CR45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41375-021-01487-9","volume":"36","author":"KI Sunthankar","year":"2022","unstructured":"Sunthankar KI, Jenkins MT, Cote CH et al (2022) Isocitrate dehydrogenase mutations are associated with altered IL-1\u03b2 responses in acute myeloid leukemia. Leukemia 36:923\u2013934. https:\/\/doi.org\/10.1038\/s41375-021-01487-9","journal-title":"Leukemia"},{"key":"5966_CR46","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DK, Eide CA et al (2017) Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep 18:3204\u20133218. https:\/\/doi.org\/10.1016\/j.celrep.2017.03.018","journal-title":"Cell Rep"},{"key":"5966_CR47","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1182\/blood-2002-11-3550","volume":"102","author":"Z Estrov","year":"2003","unstructured":"Estrov Z, Shishodia S, Faderl S et al (2003) Resveratrol blocks interleukin-1\u03b2\u2013induced activation of the nuclear transcription factor NF-\u03baB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102:987\u2013995. https:\/\/doi.org\/10.1182\/blood-2002-11-3550","journal-title":"Blood"},{"key":"5966_CR48","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.18632\/oncotarget.14220","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Volk A, Zhang J et al (2017) Sensitizing leukemia stem cells to NF-\u03baB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling. Oncotarget 8:8420\u20138435. https:\/\/doi.org\/10.18632\/oncotarget.14220","journal-title":"Oncotarget"},{"key":"5966_CR49","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood.2023022079","volume":"143","author":"H-Y Lin","year":"2024","unstructured":"Lin H-Y, Mohammadhosseini M, McClatchy J et al (2024) The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1\u03b2-mediated AML progression. Blood 143:2749\u20132762. https:\/\/doi.org\/10.1182\/blood.2023022079","journal-title":"Blood"},{"key":"5966_CR50","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro L, Will B, Bartholdy B et al (2012) Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120:1290\u20131298. https:\/\/doi.org\/10.1182\/blood-2012-01-404699","journal-title":"Blood"},{"key":"5966_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00769-z","volume":"13","author":"A M\u00e9tois","year":"2025","unstructured":"M\u00e9tois A, Bordeleau M-E, Theret L et al (2025) IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia. Biomark Res 13:61. https:\/\/doi.org\/10.1186\/s40364-025-00769-z","journal-title":"Biomark Res"},{"key":"5966_CR52","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","volume":"121","author":"M Askmyr","year":"2013","unstructured":"Askmyr M, \u00c5gerstam H, Hansen N et al (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121:3709\u20133713. https:\/\/doi.org\/10.1182\/blood-2012-09-458935","journal-title":"Blood"},{"key":"5966_CR53","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","volume":"112","author":"H \u00c5gerstam","year":"2015","unstructured":"\u00c5gerstam H, Karlsson C, Hansen N et al (2015) Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci U S A 112:10786\u201310791. https:\/\/doi.org\/10.1073\/pnas.1422749112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5966_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01586-x","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Park M, Ghoda LY et al (2024) IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J Hematol Oncol 17:67. https:\/\/doi.org\/10.1186\/s13045-024-01586-x","journal-title":"J Hematol Oncol"},{"key":"5966_CR55","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1084\/jem.20180147","volume":"215","author":"K Mitchell","year":"2018","unstructured":"Mitchell K, Barreyro L, Todorova TI et al (2018) IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med 215:1709\u20131727. https:\/\/doi.org\/10.1084\/jem.20180147","journal-title":"J Exp Med"},{"key":"5966_CR56","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41375-018-0112-2","volume":"32","author":"MM Hosseini","year":"2018","unstructured":"Hosseini MM, Kurtz SE, Abdelhamed S et al (2018) Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia 32:2374\u20132387. https:\/\/doi.org\/10.1038\/s41375-018-0112-2","journal-title":"Leukemia"},{"key":"5966_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8828","volume":"11","author":"K Melgar","year":"2019","unstructured":"Melgar K, Walker MM, Jones LM et al (2019) Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Sci Transl Med 11:eaaw8828. https:\/\/doi.org\/10.1126\/scitranslmed.aaw8828","journal-title":"Sci Transl Med"},{"key":"5966_CR58","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.3390\/cimb46040184","volume":"46","author":"K Seipel","year":"2024","unstructured":"Seipel K, Mandhair H, Bacher U, Pabst T (2024) FLT3 and IRAK4 inhibitor emavusertib in combination with BH3-mimetics in the treatment of acute myeloid leukemia. Curr Issues Mol Biol 46:2946\u20132960. https:\/\/doi.org\/10.3390\/cimb46040184","journal-title":"Curr Issues Mol Biol"},{"key":"5966_CR59","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","volume":"21","author":"MA Smith","year":"2019","unstructured":"Smith MA, Choudhary GS, Pellagatti A et al (2019) U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol 21:640\u2013650. https:\/\/doi.org\/10.1038\/s41556-019-0314-5","journal-title":"Nat Cell Biol"},{"key":"5966_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood.2022018718","volume":"142","author":"J Bennett","year":"2023","unstructured":"Bennett J, Ishikawa C, Agarwal P et al (2023) Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML. Blood 142:989\u20131007. https:\/\/doi.org\/10.1182\/blood.2022018718","journal-title":"Blood"},{"key":"5966_CR61","doi-asserted-by":"publisher","unstructured":"Ho T-C, LaMere MW, Kawano H et al (2024) Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse. bioRxiv 2024.11.09.622796 https:\/\/doi.org\/10.1101\/2024.11.09.622796","DOI":"10.1101\/2024.11.09.622796"},{"key":"5966_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1944538","volume":"10","author":"H Grauers Wiktorin","year":"2021","unstructured":"Grauers Wiktorin H, Aydin E, Christenson K et al (2021) Impact of IL-1\u03b2 and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. Oncoimmunology 10:1944538. https:\/\/doi.org\/10.1080\/2162402X.2021.1944538","journal-title":"Oncoimmunology"},{"key":"5966_CR63","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s002800050874","volume":"43","author":"SH Bernstein","year":"1999","unstructured":"Bernstein SH, Fay J, Frankel S et al (1999) A phase I study of Recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia. Cancer Chemother Pharmacol 43:141\u2013144. https:\/\/doi.org\/10.1007\/s002800050874","journal-title":"Cancer Chemother Pharmacol"},{"key":"5966_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2023.103385","volume":"71","author":"C Nicod","year":"2023","unstructured":"Nicod C, da Rocha MN, Warda W et al (2023) CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Curr Res Transl Med 71:103385. https:\/\/doi.org\/10.1016\/j.retram.2023.103385","journal-title":"Curr Res Transl Med"},{"key":"5966_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004222","volume":"10","author":"R Trad","year":"2022","unstructured":"Trad R, Warda W, Alcazer V et al (2022) Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer 10:e004222. https:\/\/doi.org\/10.1136\/jitc-2021-004222","journal-title":"J Immunother Cancer"},{"key":"5966_CR66","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","volume":"28","author":"W Warda","year":"2021","unstructured":"Warda W, Da Rocha MN, Trad R et al (2021) Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther 28:1365\u20131375. https:\/\/doi.org\/10.1038\/s41417-020-00284-3","journal-title":"Cancer Gene Ther"},{"key":"5966_CR67","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","volume":"11","author":"VR Gummadi","year":"2020","unstructured":"Gummadi VR, Boruah A, Ainan BR et al (2020) Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies. ACS Med Chem Lett 11:2374\u20132381. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00255","journal-title":"ACS Med Chem Lett"},{"key":"5966_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/01.HS9.0000843408.31385.3f","volume":"6","author":"G Garcia-Manero","year":"2022","unstructured":"Garcia-Manero G, Winer ES, DeAngelo DJ et al (2022) S129: takeaim leukemia- a phase 1\/2a study of the IRAK4 inhibitor emavusertib (CA-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed\/refractory AML or MDS. Hemasphere 6:30\u201331. https:\/\/doi.org\/10.1097\/01.HS9.0000843408.31385.3f","journal-title":"Hemasphere"},{"key":"5966_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898298","volume":"13","author":"L Magnani","year":"2022","unstructured":"Magnani L, Colantuoni M, Mortellaro A (2022) Gasdermins: new therapeutic targets in host defense, inflammatory diseases, and cancer. Front Immunol 13:898298. https:\/\/doi.org\/10.3389\/fimmu.2022.898298","journal-title":"Front Immunol"},{"key":"5966_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131766","volume":"12","author":"D Bult\u00e9","year":"2023","unstructured":"Bult\u00e9 D, Rigamonti C, Romano A, Mortellaro A (2023) Inflammasomes: mechanisms of action and involvement in human diseases. Cells 12:1766. https:\/\/doi.org\/10.3390\/cells12131766","journal-title":"Cells"},{"key":"5966_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661939","volume":"12","author":"C Zhong","year":"2021","unstructured":"Zhong C, Wang R, Hua M et al (2021) NLRP3 inflammasome promotes the progression of acute myeloid leukemia via IL-1\u03b2 pathway. Front Immunol 12:661939. https:\/\/doi.org\/10.3389\/fimmu.2021.661939","journal-title":"Front Immunol"},{"key":"5966_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15497-1","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Osswald L, Saller BS et al (2020) Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun 11:1659. https:\/\/doi.org\/10.1038\/s41467-020-15497-1","journal-title":"Nat Commun"},{"key":"5966_CR73","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4161\/cbt.29922","volume":"15","author":"J Wong","year":"2014","unstructured":"Wong J, Tran LT, Magun EA et al (2014) Production of IL-1\u03b2 by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol Ther 15:1395\u20131403. https:\/\/doi.org\/10.4161\/cbt.29922","journal-title":"Cancer Biol Ther"},{"key":"5966_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00547-8","volume":"11","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Shapiro LC, de Oliveira S et al (2021) Therapeutic targeting of the inflammasome in myeloid malignancies. Blood Cancer J 11:152. https:\/\/doi.org\/10.1038\/s41408-021-00547-8","journal-title":"Blood Cancer J"},{"key":"5966_CR75","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","volume":"38","author":"A Perzolli","year":"2024","unstructured":"Perzolli A, Koedijk JB, Zwaan CM, Heidenreich O (2024) Targeting the innate immune system in pediatric and adult AML. Leukemia 38:1191\u20131201. https:\/\/doi.org\/10.1038\/s41375-024-02217-7","journal-title":"Leukemia"},{"key":"5966_CR76","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1182\/bloodadvances.2019000792","volume":"4","author":"O Br\u00fcck","year":"2020","unstructured":"Br\u00fcck O, Dufva O, Hohtari H et al (2020) Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv 4:274\u2013286. https:\/\/doi.org\/10.1182\/bloodadvances.2019000792","journal-title":"Blood Adv"},{"key":"5966_CR77","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz L, S\u00e1nchez-Aguilera A, Mart\u00edn-P\u00e9rez D et al (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512:78\u201381. https:\/\/doi.org\/10.1038\/nature13383","journal-title":"Nature"},{"key":"5966_CR78","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41375-020-0827-8","volume":"34","author":"MZ Ratajczak","year":"2020","unstructured":"Ratajczak MZ, Bujko K, Cymer M et al (2020) The Nlrp3 inflammasome as a rising star in studies of normal and malignant hematopoiesis. Leukemia 34:1512\u20131523. https:\/\/doi.org\/10.1038\/s41375-020-0827-8","journal-title":"Leukemia"},{"key":"5966_CR79","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.18632\/aging.102409","volume":"11","author":"L Shi","year":"2019","unstructured":"Shi L, Zhao Y, Fei C et al (2019) Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation. Aging 11:9626\u20139642. https:\/\/doi.org\/10.18632\/aging.102409","journal-title":"Aging"},{"key":"5966_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/genes13122281","volume":"13","author":"K Huang","year":"2022","unstructured":"Huang K, Xie L, Wang F (2022) A novel defined pyroptosis-related gene signature for the prognosis of acute myeloid leukemia. Genes 13:2281. https:\/\/doi.org\/10.3390\/genes13122281","journal-title":"Genes"},{"key":"5966_CR81","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/s41375-022-01662-6","volume":"36","author":"W Kong","year":"2022","unstructured":"Kong W, He L, Zhu J et al (2022) An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia. Leukemia 36:2384\u20132395. https:\/\/doi.org\/10.1038\/s41375-022-01662-6","journal-title":"Leukemia"},{"key":"5966_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01777-6","volume":"22","author":"M Luciano","year":"2024","unstructured":"Luciano M, Sieberer H, Krenn PW et al (2024) Targeting NLRP3 inhibits AML progression by inducing PERK\/eIF2-mediated apoptosis. Cell Commun Signal 22:424. https:\/\/doi.org\/10.1186\/s12964-024-01777-6","journal-title":"Cell Commun Signal"},{"key":"5966_CR83","doi-asserted-by":"publisher","first-page":"14088","DOI":"10.18632\/aging.203028","volume":"13","author":"J Liu","year":"2021","unstructured":"Liu J, Zhao M, Feng X et al (2021) Expression and prognosis analyses of CASP1 in acute myeloid leukemia. Aging 13:14088\u201314108. https:\/\/doi.org\/10.18632\/aging.203028","journal-title":"Aging"},{"key":"5966_CR84","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.3892\/ol.2017.7177","volume":"14","author":"Y Jia","year":"2017","unstructured":"Jia Y, Zhang C, Hua M et al (2017) Aberrant NLRP3 inflammasome associated with Aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia. Oncol Lett 14:7031\u20137044. https:\/\/doi.org\/10.3892\/ol.2017.7177","journal-title":"Oncol Lett"},{"key":"5966_CR85","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.21037\/tcr-24-1403","volume":"13","author":"J Zhao","year":"2024","unstructured":"Zhao J, Cui Y, Zhou H et al (2024) FLT3 mutation-related immune checkpoint molecule absent in melanoma 2 (AIM2) contributes to immune infiltration in pediatric and adult acute myeloid leukemia: evidence from bioinformatics analysis. Transl Cancer Res 13:6255\u20136272. https:\/\/doi.org\/10.21037\/tcr-24-1403","journal-title":"Transl Cancer Res"},{"key":"5966_CR86","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/2767-9764.CRC-23-0507","volume":"4","author":"T Baba","year":"2024","unstructured":"Baba T, Tomaru U, Hirao A et al (2024) Autophagy inhibition-induced cytosolic DNA sensing combined with differentiation therapy induces irreversible myeloid differentiation in leukemia cells. Cancer Res Commun 4:849\u2013860. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0507","journal-title":"Cancer Res Commun"},{"key":"5966_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967989","volume":"13","author":"H Cheng","year":"2022","unstructured":"Cheng H, Chen L, Huang M et al (2022) Hunting down NLRP3 inflammasome: an executioner of radiation-induced injury. Front Immunol 13:967989. https:\/\/doi.org\/10.3389\/fimmu.2022.967989","journal-title":"Front Immunol"},{"key":"5966_CR88","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.92885","volume":"13","author":"C Wang","year":"2024","unstructured":"Wang C, Kaur K, Xu C et al (2024) Chemotherapy activates inflammasomes to cause inflammation-associated bone loss. Elife 13:RP92885. https:\/\/doi.org\/10.7554\/eLife.92885","journal-title":"Elife"},{"key":"5966_CR89","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","volume":"11","author":"KAD Sauter","year":"2011","unstructured":"Sauter KAD, Wood LJ, Wong J et al (2011) Doxorubicin and daunorubicin induce processing and release of interleukin-1\u03b2 through activation of the NLRP3 inflammasome. Cancer Biol Ther 11:1008\u20131016. https:\/\/doi.org\/10.4161\/cbt.11.12.15540","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"5966_CR90","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.7150\/ijms.96627","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Hou Q, Chang T et al (2024) Analysis of prognostic biomarker models of TXNIP\/NLRP3\/IL1B inflammasome pathway in patients with acute myeloid leukemia. Int J Med Sci 21(8):1438\u20131446. https:\/\/doi.org\/10.7150\/ijms.96627","journal-title":"Int J Med Sci"},{"key":"5966_CR91","doi-asserted-by":"publisher","first-page":"103758","DOI":"10.1016\/j.htct.2025.103758","volume":"47","author":"BG Santos de Macedo","year":"2025","unstructured":"Santos de Macedo BG, Albuquerque de Melo M, Pereira-Martins DA et al (2025) A common ground: an in Silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia. Hematol Transfus Cell Ther 47:103758. https:\/\/doi.org\/10.1016\/j.htct.2025.103758","journal-title":"Hematol Transfus Cell Ther"},{"key":"5966_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659253","volume":"11","author":"N van Gils","year":"2021","unstructured":"van Gils N, Denkers F, Smit L (2021) Escape from treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia. Front Oncol 11:659253. https:\/\/doi.org\/10.3389\/fonc.2021.659253","journal-title":"Front Oncol"},{"key":"5966_CR93","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AAB, Chae JJ et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248\u2013255. https:\/\/doi.org\/10.1038\/nm.3806","journal-title":"Nat Med"},{"key":"5966_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02538","volume":"10","author":"A Zahid","year":"2019","unstructured":"Zahid A, Li B, Kombe AJK et al (2019) Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 10:2538. https:\/\/doi.org\/10.3389\/fimmu.2019.02538","journal-title":"Front Immunol"},{"key":"5966_CR95","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708689","volume":"10","author":"Y Huang","year":"2018","unstructured":"Huang Y, Jiang H, Chen Y et al (2018) Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med 10:e8689. https:\/\/doi.org\/10.15252\/emmm.201708689","journal-title":"EMBO Mol Med"},{"key":"5966_CR96","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, Swartzwelter B, Gamboni F et al (2018) OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A 115:E1530\u2013E1539. https:\/\/doi.org\/10.1073\/pnas.1716095115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5966_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630479","volume":"9","author":"ANR Weber","year":"2021","unstructured":"Weber ANR (2021) Targeting the NLRP3 inflammasome via BTK. Front Cell Dev Biol 9:630479. https:\/\/doi.org\/10.3389\/fcell.2021.630479","journal-title":"Front Cell Dev Biol"},{"key":"5966_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106947","volume":"122","author":"SC Fisch","year":"2022","unstructured":"Fisch SC, Tuscano JM, Qi L, Jonas BA (2022) Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy. Leuk Res 122:106947. https:\/\/doi.org\/10.1016\/j.leukres.2022.106947","journal-title":"Leuk Res"},{"key":"5966_CR99","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","volume":"4","author":"G Huls","year":"2020","unstructured":"Huls G, Chitu DA, Pabst T et al (2020) Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Adv 4:4267\u20134277. https:\/\/doi.org\/10.1182\/bloodadvances.2020002846","journal-title":"Blood Adv"},{"key":"5966_CR100","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.05.008","volume":"19","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Jonas BA, Graef T et al (2019) Clinical experience with ibrutinib alone or in combination with either cytarabine or azacitidine in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 19:509-515e1. https:\/\/doi.org\/10.1016\/j.clml.2019.05.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5966_CR101","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41591-018-0082-y","volume":"24","author":"DC Johnson","year":"2018","unstructured":"Johnson DC, Taabazuing CY, Okondo MC et al (2018) DPP8\/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med 24:1151\u20131156. https:\/\/doi.org\/10.1038\/s41591-018-0082-y","journal-title":"Nat Med"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05966-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05966-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05966-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:05:10Z","timestamp":1766160310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05966-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5966"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05966-5","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflicts of interest.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\u00a0"}}],"article-number":"443"}}